The combination of the antibody amivantamab and lazertinib, a drug targeting EGFR, shows better clinical benefits compared to standard treatment in patients with advanced or metastatic non-small cell lung cancer with EGFR gene mutations who also present one of these poor prognosti markers: brain and/or liver metastases, p53 gene co-mutations, or the presence of circulating tumor DNA.